Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
If progression continues or threatens your central vision, we discuss more active treatment options
The SURMOUNT phase 3 program (SURMOUNT-1, NCT04184622) studied tirzepatide in adults with obesity or overweight without type 2 diabetes, with body weight as the primary endpoint over 72 weeks
Past results do not predict future outcomes
For example, if you normally inject on Monday and realize on Wednesday that you forgot, inject on Wednesday and then go back to Monday the following week
US$ 24.01
US$ 29.37
US$ 29.49
